Thursday, 16 Aug 2018

You are here

Can DMARDs Delay Rheumatoid Onset?

Preclinical rheumatoid arthritis (RA) is a hot new area wherein at risk individuals (seropositive, first degree relatives of RA patients, etc.) are being studied to assess the triggers that lead to progression to RA or whether therapies can be used to avert the onset of RA.

Hilliquin and colleagues undertook a systematic literature review and meta-analysis to assess if there are randomised controlled trials of disease-modifying antirheumatic drugs (DMARDs) or glucocorticoids used in at risk individuals - those with genetic and/or environmental risk factors and/or systemic autoimmunity associated with RA, without clinical synovitis/arthritis. 

They identified 10 trials that included 1156 patients, with mean symptom duration 16.2±12.6 weeks.

In those with  arthralgia, and without arthritis (people at risk of RA), two available studies failed to show significant reduction in RA occurrence at week 52 or more (pooled OR 0.74, 95% CI 0.37 to 1.49).

For people with undifferentiated arthritis, seven studies revealed significant risk reduction with OR 0.73(95% CI 0.56 to 0.97) in the development of RA.

This metanalysis shows that early therapeutic intervention may significantly reduce the risk of RA onset but only those with undifferentiated arthritis.

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tumor Necrosis Factor Inhibitors Do Not Increase the Risk of Cancer Recurrence

There is a large body of data that shows tumor necrosis factor inhibitors (TNFi) use in rheumatoid arthritis (RA) confers the same risk as that seen in RA - meaning there is no increase over and above that incurred by inflammation and RA itself.  There are fewer studies about whether it is safe to use a TNFi in someone with a pre-existing history of cancer.

Cardiovascular Benefits of Maintaining Biologic Therapy

An Australian prospective study of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) has shown that sustained use of tumour necrosis factor (TNFi) inhibitors or biologics can reduce the risks of cardiovascular events (CVEs).

Maternal RA Increases Offspring Risk of Autoimmune Disorders

A Danish population study suggests that fetal exposure to maternal rheumatoid arthritis results in an increased offspring risk of thyroid disease, epilepsy and RA, compared to children born to mothers without RA.

The Fate of Palindromic Rheumatism

 

Palindromic rheumatism (PR) is an intermittent inflammatory arthropathy with episodes of arthritis and/or periarticular inflammation that wax and wane over time. It is thought that up to one-third of such patients may go on to develop rheumatoid arthritis (RA).

Consensus Guidelines for Methotrexate in Juvenile Idiopathic Arthritis

A consensus panel was convened to develop consensus-based clinical and therapeutic recommendations for the use of methotrexate (MTX) in the management of Juvenile Idiopathic Arthritis (JIA) patients.